Abstract: Ring opening reactions of benzoxazinones (6a,b) with oxygen, nitrogen and carbon nucleophiles gave the corresponding benzoates (7), benzamides (8), acrylamides (9 and 11) and the cyanoacetamides (10 a,b). Condensation of compounds (6) with amines under drastic conditions, Yield:ed the quinazolinone derivatives (13). When reacted with thiosemicarbazide and/or phenyl thiourea, compound 6b gave the triazole (14) and / or pyrimidoquinazolinone (15). Some of the new compounds (7a, 7b, 7c, 8b, 8d, 9, 11, 13a, 13b, 14 and 15) were tested for cytotoxic activity using tumor cell line (MCF7).
INTRODUCTION

RESULTS AND DISCUSSION
Tranilast (1) is an antiallergic agent that blocks the The reported biological and pharmacological release of chemical mediators, such as histamine and activities of benzoxazines initiated our interest in studying leukotrienes from mast cells [1] [2] [3] [4] [5] [6] . Tranilast (1) possesses the behavior of this ring system towards a variety of antitumor effects (i.e it potentiated the inhibition of the nucleophiles. The desired benzoxazinones (6a,b) were tumor growth induced by several anticancer drugs [7, 8] .
prepared by condensation of 2-propenoyl chloride It possesses pharmacological approaches to cestenosis derivatives (4a,b) with anthranilic acid or its 5-bromo preventation [9] and for therapeutic interventions in heart derivative in pyridine or triethylamine/toluene via the failure [10] . Amides (2) (analogues of Tranilast), showed intermediacy of benzoic acid derivatives (5a,b) [17] [18] [19] [20] . characteristic activities against smooth muscle cell
The structures of 5b and 6b were established by proliferation [11] .
comparison with the authentic samples [20] . Scheme 1.
On the other hand, benzoxazinones and (3,4-dimethoxyphenylmethylene) malononitrile (12) [21] , quinazolinones (3) (prepared by cyclization of (1) and/or which was identified authentically by condensation of 3,4-(2)), still have pronounced characteristic biological and dimethoxybenzaldehyde with malononitrile in piperidine pharmacological activities. [12] [13] [14] [15] [16] .
(Scheme 2).
The expected 2-acrylamido benzoates (7a-c) were obtained by treatment of benzoxazinones (6a,b) with ethanol and/or 1-butanol in presence of pyridine (Scheme 2).
Ring opening of 6a,b with primary amines, such as benzylamine, ethanolamine and 4-methoxyaniline, in dioxane gave the corresponding benzamide derivatives (8a-f), while with secondary amines, such as piperidine, (6a) gave a mixture of the acrylamide (9) and cyanoacetamide (10a) while 6b gave 10b only as a sole product (Scheme 2).
Condensation of 6b with malononitrile in presence of pyridine afforded a mixture of the acrylamide (11) and 2-Scheme 1:
Fusion of 6a,b with ammonium acetate and/or (Scheme 2), through the ring opening-ring closure aromatic amines, like, 4-methoxyanilineor 3-chloroaniline process, followed by addition on the á,â-unsaturated gave the corresponding quinazolinones (13a-f) (Scheme nitrile with subsequent dehydrogenation of the pyrimidine 2). Furthermore, fusion of 6b with thiosemicarbazide in thione moiety. neat at 180°C gave the triazole derivative (14) (Scheme 2), via ring opening of benzoxazinone ring, followed by ring Antitumor Activity: The tranilast and its analogous were closure at the hydrazide moiety.
tested for cytotoxic activity against MCF7 (Breast On the other hand, refluxing 6b with phenyl thiourea Carcinoma Cell Lin), Human tumor cell lines were obtained in pyridine, Yield:ed the pyrimidoquinazolinone (15) in liquid nitrogen (-180°C) from the American Type Cells were plated in 96-multiwell plate (104 cells/well) for 24 hrs before treatment with the compounds to allow attachment of cell to the wall of the plate. Different concentrations of the compound under test (0, 1, 2.5, 5 and 10 µg/ml) were added to the cell monolayer triplicate wells were prepared for each individual dose.
Monolayer cells were incubated with the compounds for 48 hrs at 37°C and in atmosphere of 5% CO . 2 After 48 hrs, cells were fixed, washed and stained with Sulfo-Rhodamine-B stain. Excess stain was washed with acetic acid and attached stain was recovered with Tris EDTA (Ethylene Diamine Tetra Acetic acid) buffer. Color intensity was measured in an ELISA (Enzyme Linked Immuno Sorbent Assay) reader. The relation between surviving fraction and drug conc. is plotted to get the survival curve of each tumor cell line after the specified compound.
CONCLUSION
The antitumor activity results indicated that, all the eleven derivatives showed antitumor activity against tested MCF7 (Breast Carcinoma Cell Line) but with varying intensities in comparison to the standard drug: Tranilast. Moreover nine compounds showed higher cytotoxic activity than Tranilast and only two compounds showed lower cytotoxic activity than Tranilast, compounds 7b and13a showed the highest cytotoxic activity (IC50 equals 7.7 ug/ml).
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The survival curves of each tumor cell line after the specified compound. General method for synthesis of 7a-c: Refluxing of 6a (0.01 mol, 3.83 g) and / or 6b (0.01 mol, 3.34 g), in ethanol and/or n-butanol (20 mL) with few drops of pyridine for 4hrs. After cooling, the precipitate was collected by filtration and recrystallised from a suitable solvent to give 7a-c. 
Experimental
(E)-Ethyl 5-bromo-2-(2-cyano-3-(4-methoxyphenyl
